Sysmex (OTCMKTS:SSMXY) Shares Gap Down – Should You Sell?

Sysmex Corporation ADR (OTCMKTS:SSMXY)’s stock price gapped down before the market opened on Thursday . The stock had previously closed at $9.04, but opened at $8.59. Sysmex shares last traded at $8.91, with a volume of 1,823 shares traded.

Wall Street Analysts Forecast Growth

Separately, Citigroup cut shares of Sysmex from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 16th. One research analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold”.

Sysmex Price Performance

The company has a market cap of $5.50 billion, a price-to-earnings ratio of 23.00 and a beta of 1.10. The company has a current ratio of 3.26, a quick ratio of 2.44 and a debt-to-equity ratio of 0.12. The company’s 50 day moving average price is $8.75 and its 200 day moving average price is $9.16.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). Sysmex had a net margin of 7.13% and a return on equity of 7.23%. The company had revenue of $877.92 million during the quarter, compared to analysts’ expectations of $862.45 million. Sysmex has set its FY 2026 guidance at 0.370-0.370 EPS. Equities research analysts forecast that Sysmex Corporation ADR will post 0.37 earnings per share for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.